Publications by authors named "F Yocca"

Claim this Profile
D
Dexmedetomidine potently and reversibly regulates stress-mediated behaviors.
Frank D Yocca, Dinesh K Dhull, Subhendu Seth, Manisha Chugh, Sameer Sharma

Front Pharmacol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial.
Jermaine D Jones, Lavanya Rajachandran, Frank Yocca, Robert Risinger, Michael De Vivo

Am J Drug Alcohol Abuse· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial.
Leslie Citrome, Sheldon H Preskorn, John Lauriello, John H Krystal, Rishi Kakar, Frank D Yocca

J Clin Psychiatry· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial.
Sheldon H Preskorn, Scott Zeller, Leslie Citrome, Jeffrey Finman, Joseph F Goldberg, Frank D Yocca

JAMA· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the δ opioid agonist AZD2327 upon operant behaviors and assessment of its potential for abuse.
T J Hudzik, M R Pietras, R Caccese, K H Bui, F Yocca

Pharmacol Biochem Behav· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis